Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Marloes A. Wijdeven"'
Autor:
Marloes A. Wijdeven, Remon van Geel, Jorin H. Hoogenboom, Jorge M. M. Verkade, Brian M. G. Janssen, Inge Hurkmans, Laureen de Bever, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™
Externí odkaz:
https://doaj.org/article/848d309b246a42aca0115d74462db631
Autor:
Jorge M. M. Verkade, Marloes A. Wijdeven, Remon van Geel, Brian M. G. Janssen, Sander S. van Berkel, Floris L. van Delft, Antibodies Editorial Office
Publikováno v:
Antibodies, Vol 7, Iss 3, p 34 (2018)
The conflict of interest section of the published paper [1] has been updated as follows[...]
Externí odkaz:
https://doaj.org/article/fb2f870787b6466e95da8a6ea1543a7a
Autor:
Jorge M. M. Verkade, Marloes A. Wijdeven, Remon van Geel, Brian M. G. Janssen, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
Antibodies, Vol 7, Iss 1, p 12 (2018)
Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with littl
Externí odkaz:
https://doaj.org/article/3467b0204f6846e79773a9ba2403fa4a
Autor:
Bauke Albada, Jorick J. Bruins, Lianne P. W. M. Lelieveldt, Marloes A. Wijdeven, Floris L. van Delft, Johannes A. M. Damen
Publikováno v:
Bioconjugate Chemistry 32 (2021) 10
Bioconjugate Chemistry
Bioconjugate Chemistry, 32(10), 2167-2172
Bioconjugate Chemistry
Bioconjugate Chemistry, 32(10), 2167-2172
The availability of tools to generate homogeneous and stable antibody conjugates without recombinant DNA technology is a valuable asset in fields spanning from in vitro diagnostics to in vivo imaging and therapeutics. We present here a general approa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4b26c96c0033afed81ce67ed8187d7
https://research.wur.nl/en/publications/non-genetic-generation-of-antibody-conjugates-based-on-chemoenzym
https://research.wur.nl/en/publications/non-genetic-generation-of-antibody-conjugates-based-on-chemoenzym
Autor:
Marloes A. Wijdeven, Bernhard Westermann, Berry G. M. Bögels, Floris P. J. T. Rutjes, Sander S. van Berkel
Publikováno v:
European Journal of Organic Chemistry, 2012, 3543-3559
European Journal of Organic Chemistry, 2012, 19, pp. 3543-3559
European Journal of Organic Chemistry, 2012, 19, pp. 3543-3559
Isocyanide-based multicomponent reactions (IMCRs) can be considered one of the breakthrough reaction classes of the last century. Moreover, asymmetric IMCRs have recently developed into powerful reactions for the versatile synthesis of highly complex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7138a4d7bbd4ff706ae5e2a76643a9ce
https://doi.org/10.1002/ejoc.201200030
https://doi.org/10.1002/ejoc.201200030
Autor:
Marloes A. Wijdeven, Sander S. van Berkel, Floris L. van Delft, Jorge M. M. Verkade, Brian Maria Gerardus Janssen, Remon Van Geel
Publikováno v:
Cancer Research. 78:3815-3815
We have found that conjugation of toxic payloads to the native glycan of a monoclonal antibody by chemoenzymatic remodeling (GlycoConnect™ technology) consistently provides antibody-drug conjugates (ADCs) with enhanced therapeutic index (TI) increa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::510d25d8f4e93b2c9b5315d0e819f7d3
https://doi.org/10.1158/1538-7445.am2018-3815
https://doi.org/10.1158/1538-7445.am2018-3815
Publikováno v:
Tetrahedron, 66, 5623-5636
Tetrahedron, 66, 30, pp. 5623-5636
Tetrahedron, 66, 30, pp. 5623-5636
The synthetic versatility of three chemoenzymatically prepared hydroxypiperidine building blocks has been explored, resulting in a library of enantiopure functionalized piperidines. Key steps involved N-acyliminium ion-mediated CC-bond formation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76496df67d02750a10ec0b14562952f3
https://doi.org/10.1016/j.tet.2010.05.089
https://doi.org/10.1016/j.tet.2010.05.089
Publikováno v:
European Journal of Organic Chemistry. 2010:2831-2844
The 3-hydroxypiperidine moiety is a privileged scaffold that is encountered in many bioactive compounds and natural products. This review summarizes the investigations ofvarious research groups concerning the synthesis of natural products containing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::026e869dd5c506a24e2dc2efe0886bdc
https://doi.org/10.1002/ejoc.200901494
https://doi.org/10.1002/ejoc.200901494
Autor:
Sander S. van Berkel, Floris L. van Delft, Remon Van Geel, Jorge M. M. Verkade, Brian Maria Gerardus Janssen, Marloes A. Wijdeven
Publikováno v:
Antibodies, Vol 7, Iss 1, p 12 (2018)
Antibodies; Volume 7; Issue 1; Pages: 12
Antibodies
Antibodies; Volume 7; Issue 1; Pages: 12
Antibodies
Despite tremendous efforts in the field of targeted cancer therapy with antibody–drug conjugates (ADCs), attrition rates have been high. Historically, the priority in ADC development has been the selection of target, antibody, and toxin, with littl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86f8516adeec579e4d92e1be9983c32
https://doi.org/10.3390/antib7010012
https://doi.org/10.3390/antib7010012
Autor:
Floris L. van Delft, Jorge M. M. Verkade, Marloes A. Wijdeven, Remon Van Geel, Anna Agnieska Wasiel, Ryan Heesbeen, Sander S. van Berkel
Publikováno v:
Bioconjugate chemistry. 26(11)
A robust, generally applicable, nongenetic technology is presented to convert monoclonal antibodies into stable and homogeneous ADCs. Starting from a native (nonengineered) mAb, a chemoenzymatic protocol allows for the highly controlled attachment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ee12e19d6a2ad343081632e515d332
https://pubmed.ncbi.nlm.nih.gov/26061183
https://pubmed.ncbi.nlm.nih.gov/26061183